- Home
- ANGO vs PGEN Comparison
ANGO vs PGEN Comparison
Compare ANGO & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANGO
- PGEN
- Stock Information
- Founded
- ANGO 1988
- PGEN 1998
- Country
- ANGO United States
- PGEN United States
- Employees
- ANGO N/A
- PGEN N/A
- Industry
- ANGO Medical/Dental Instruments
- PGEN Biotechnology: Pharmaceutical Preparations
- Sector
- ANGO Health Care
- PGEN Health Care
- Exchange
- ANGO Nasdaq
- PGEN Nasdaq
- Market Cap
- ANGO 279.1M
- PGEN 292.6M
- IPO Year
- ANGO 2004
- PGEN N/A
- Fundamental
- Price
- ANGO $8.86
- PGEN $0.76
- Analyst Decision
- ANGO Strong Buy
- PGEN Buy
- Analyst Count
- ANGO 4
- PGEN 5
- Target Price
- ANGO $12.00
- PGEN $7.00
- AVG Volume (30 Days)
- ANGO 615.8K
- PGEN 1.1M
- Earning Date
- ANGO 01-08-2025
- PGEN 11-14-2024
- Dividend Yield
- ANGO N/A
- PGEN N/A
- EPS Growth
- ANGO N/A
- PGEN N/A
- EPS
- ANGO N/A
- PGEN N/A
- Revenue
- ANGO $292,726,000.00
- PGEN $3,963,000.00
- Revenue This Year
- ANGO N/A
- PGEN N/A
- Revenue Next Year
- ANGO $7.69
- PGEN $426.76
- P/E Ratio
- ANGO N/A
- PGEN N/A
- Revenue Growth
- ANGO N/A
- PGEN N/A
- 52 Week Low
- ANGO $5.26
- PGEN $0.65
- 52 Week High
- ANGO $9.58
- PGEN $1.93
- Technical
- Relative Strength Index (RSI)
- ANGO 61.62
- PGEN 43.22
- Support Level
- ANGO $8.45
- PGEN $0.76
- Resistance Level
- ANGO $9.58
- PGEN $0.78
- Average True Range (ATR)
- ANGO 0.49
- PGEN 0.06
- MACD
- ANGO 0.05
- PGEN -0.00
- Stochastic Oscillator
- ANGO 65.79
- PGEN 34.93
About ANGO AngioDynamics Inc.
AngioDynamics Inc designs manufactures, and sells medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Geographically, the company derives a majority of its revenue from the United States from sale of Med Tech and Med Device.
About PGEN Precigen Inc.
Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.